{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:25:13Z","timestamp":1783401913316,"version":"3.54.6"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T00:00:00Z","timestamp":1526688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Individualized antihypertensive treatment based on specific biomarkers such as renin may lead to more effective blood pressure control in patients with newly diagnosed essential hypertension. Recent studies suggested that the plasma aldosterone-to-renin ratio (ARR) may also be a candidate predictor for this purpose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess whether the ARR is associated with the blood pressure response to antihypertensive treatment in patients with newly diagnosed hypertension.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this prospective cohort study in primary care, we determined the ARR in patients with newly diagnosed hypertension prior to starting treatment. Treatment was categorized in five groups: no medication, use of angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker, use of calcium channel blocker, use of diuretic, or use of beta blocker. We examined the relation between the ARR and blood pressure response within 1 year of treatment, taking into account the type of antihypertensive treatment and adjusting for gender, age, baseline blood pressure, and comorbidity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Out of 304 patients, we used 947 measurements (727 no medication, 220 medication) for analysis. There was no association between the ARR and the response in blood pressure, and this applied to each treatment group. Target blood pressure, defined as systolic blood pressure &amp;lt;140 mmHg, was reached in 31% of patients. There was no association between the ARR and reaching target blood pressure (OR 1.002, 95% CI 0.983\u20131.022).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The ARR is not associated with the response in blood pressure within 1 year of antihypertensive treatment in primary care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/fampra\/cmy039","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T11:11:28Z","timestamp":1524568288000},"page":"154-161","source":"Crossref","is-referenced-by-count":2,"title":["Is the plasma aldosterone-to-renin ratio associated with blood pressure response to treatment in general practice?"],"prefix":"10.1093","volume":"36","author":[{"given":"Sabine C","family":"K\u00e4yser","sequence":"first","affiliation":[{"name":"Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca W M","family":"Schalk","sequence":"first","affiliation":[{"name":"Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J C","family":"de Grauw","sequence":"first","affiliation":[{"name":"Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjard R","family":"Schermer","sequence":"first","affiliation":[{"name":"Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier P","family":"Akkermans","sequence":"first","affiliation":[{"name":"Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Radboud Institute for Health Sciences, IQ Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques W M","family":"Lenders","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Deinum","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion C J","family":"Biermans","sequence":"first","affiliation":[{"name":"Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,19]]},"reference":[{"key":"2020041602254271800_CIT0001","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"2020041602254271800_CIT0002","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2020041602254271800_CIT0003","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"2020041602254271800_CIT0004","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"2020041602254271800_CIT0005","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"},{"key":"2020041602254271800_CIT0006","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00004872-200204000-00037","article-title":"Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs","volume":"20","author":"Deary","year":"2002","journal-title":"J Hypertens"},{"key":"2020041602254271800_CIT0007","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(98)07614-4","article-title":"Optimisation of antihypertensive treatment by crossover rotation of four major classes","volume":"353","author":"Dickerson","year":"1999","journal-title":"Lancet"},{"key":"2020041602254271800_CIT0008","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-141-8-200410190-00009","article-title":"Systematic review: antihypertensive drug therapy in black patients","volume":"141","author":"Brewster","year":"2004","journal-title":"Ann Intern Med"},{"key":"2020041602254271800_CIT0009","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.280.13.1168","article-title":"Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"280","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"2020041602254271800_CIT0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/fampra\/cmx075","article-title":"Patient characteristics do not predict the individual response to antihypertensive medication: a cross-over trial","volume":"35","author":"van der Wel","year":"2018","journal-title":"Fam Pract"},{"key":"2020041602254271800_CIT0011","doi-asserted-by":"crossref","first-page":"831","DOI":"10.7326\/0003-4819-75-6-831","article-title":"Hypertension and low plasma renin activity: presumptive evidence for mineralocorticoid excess","volume":"75","author":"Spark","year":"1971","journal-title":"Ann Intern Med"},{"key":"2020041602254271800_CIT0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-72-1-9","article-title":"Suppressed plasma renin activity in essential hypertension. Roles of plasma volume, blood pressure, and sympathetic nervous system","volume":"72","author":"Jose","year":"1970","journal-title":"Ann Intern Med"},{"key":"2020041602254271800_CIT0013","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1373\/clinchem.2015.242990","article-title":"A renin-ssance in primary aldosteronism testing: obstacles and opportunities for screening, diagnosis, and management","volume":"61","author":"Raizman","year":"2015","journal-title":"Clin Chem"},{"key":"2020041602254271800_CIT0014","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0889-8529(02)00013-0","article-title":"Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature","volume":"31","author":"Montori","year":"2002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020041602254271800_CIT0015","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.3399\/bjgp18X694589","article-title":"Prevalence of primary aldosteronism in primary care: a cross-sectional study","volume":"68","author":"K\u00e4yser","year":"2018","journal-title":"Br J Gen Pract"},{"key":"2020041602254271800_CIT0016","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2020041602254271800_CIT0017","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a Cohort Study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"key":"2020041602254271800_CIT0018","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2020041602254271800_CIT0019","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2020041602254271800_CIT0020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"2020041602254271800_CIT0021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/fampra\/9.3.330","article-title":"International primary care classifications: the effect of fifteen years of evolution","volume":"9","author":"Lamberts","year":"1992","journal-title":"Fam Pract"},{"key":"2020041602254271800_CIT0022","volume-title":"Multilevel Analysis. An Antroduction to Basic and Advanced Multilevel Analysis","author":"Snijders","year":"1999","edition":"2"},{"issue":"12 Pt 1","key":"2020041602254271800_CIT0023","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","article-title":"Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens"},{"key":"2020041602254271800_CIT0024","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/HJR.0b013e328337cca2","article-title":"Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example","volume":"17","author":"van Dis","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2020041602254271800_CIT0025","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"2020041602254271800_CIT0026","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.jhh.1001320","article-title":"Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity","volume":"16","author":"Lim","year":"2002","journal-title":"J Hum Hypertens"},{"key":"2020041602254271800_CIT0027","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/HJH.0b013e328332b79b","article-title":"Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO","volume":"28","author":"Parthasarathy","year":"2010","journal-title":"J Hypertens"},{"key":"2020041602254271800_CIT0028","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2261-7-14","article-title":"Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study","volume":"7","author":"Parthasarathy","year":"2007","journal-title":"BMC Cardiovasc Disord"},{"key":"2020041602254271800_CIT0029","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0091270003258189","article-title":"Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy","volume":"43","author":"Prisant","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"2020041602254271800_CIT0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/HJH.0000000000001671","article-title":"Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension","volume":"36","author":"Bazoukis","year":"2018","journal-title":"J Hypertens"},{"key":"2020041602254271800_CIT0031","doi-asserted-by":"publisher","first-page":"CD001841","DOI":"10.1002\/14651858.CD001841.pub2","article-title":"First-line drugs for hypertension","volume":"3","author":"Wright","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2020041602254271800_CIT0032","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.5114\/aoms.2017.68650","article-title":"Lifestyle measures for treating hypertension","volume":"13","author":"Aronow","year":"2017","journal-title":"Arch Med Sci"},{"key":"2020041602254271800_CIT0033","first-page":"2083","article-title":"Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial","volume":"289","author":"Appel","year":"2003","journal-title":"JAMA"},{"key":"2020041602254271800_CIT0034","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11906-010-0156-9","article-title":"Aldosterone to renin ratio as a predictor of diuretic response","volume":"12","author":"Atlas","year":"2010","journal-title":"Curr Hypertens Rep"}],"container-title":["Family Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/fampra\/article-pdf\/36\/2\/154\/33046169\/cmy039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/fampra\/article-pdf\/36\/2\/154\/33046169\/cmy039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T06:26:07Z","timestamp":1587018367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/fampra\/article\/36\/2\/154\/4999776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,19]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,5,19]]},"published-print":{"date-parts":[[2019,3,20]]}},"URL":"https:\/\/doi.org\/10.1093\/fampra\/cmy039","relation":{},"ISSN":["1460-2229"],"issn-type":[{"value":"1460-2229","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,5,19]]}}}